224 related articles for article (PubMed ID: 31601569)
1. A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma.
Furman WL; Federico SM; McCarville MB; Shulkin BL; Davidoff AM; Krasin MJ; Sahr N; Sykes A; Wu J; Brennan RC; Bishop MW; Helmig S; Stewart E; Navid F; Triplett B; Santana VM; Bahrami A; Anthony G; Yu AL; Hank J; Gillies SD; Sondel PM; Leung WH; Pappo AS
Clin Cancer Res; 2019 Nov; 25(21):6320-6328. PubMed ID: 31601569
[TBL] [Abstract][Full Text] [Related]
2. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.
Furman WL; McCarville B; Shulkin BL; Davidoff A; Krasin M; Hsu CW; Pan H; Wu J; Brennan R; Bishop MW; Helmig S; Stewart E; Navid F; Triplett B; Santana V; Santiago T; Hank JA; Gillies SD; Yu A; Sondel PM; Leung WH; Pappo A; Federico SM
J Clin Oncol; 2022 Feb; 40(4):335-344. PubMed ID: 34871104
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
Federico SM; McCarville MB; Shulkin BL; Sondel PM; Hank JA; Hutson P; Meagher M; Shafer A; Ng CY; Leung W; Janssen WE; Wu J; Mao S; Brennan RC; Santana VM; Pappo AS; Furman WL
Clin Cancer Res; 2017 Nov; 23(21):6441-6449. PubMed ID: 28939747
[No Abstract] [Full Text] [Related]
4. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
Shusterman S; Naranjo A; Van Ryn C; Hank JA; Parisi MT; Shulkin BL; Servaes S; London WB; Shimada H; Gan J; Gillies SD; Maris JM; Park JR; Sondel PM
Clin Cancer Res; 2019 Oct; 25(20):6044-6051. PubMed ID: 31358541
[TBL] [Abstract][Full Text] [Related]
5. Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
Talleur AC; Triplett BM; Federico S; Mamcarz E; Janssen W; Wu J; Shook D; Leung W; Furman WL
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1910-1917. PubMed ID: 28733263
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors.
Bishop MW; Hutson PR; Hank JA; Sondel PM; Furman WL; Meagher MM; Navid F; Santana VM
MAbs; 2020; 12(1):1773751. PubMed ID: 32643524
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.
Navid F; Sondel PM; Barfield R; Shulkin BL; Kaufman RA; Allay JA; Gan J; Hutson P; Seo S; Kim K; Goldberg J; Hank JA; Billups CA; Wu J; Furman WL; McGregor LM; Otto M; Gillies SD; Handgretinger R; Santana VM
J Clin Oncol; 2014 May; 32(14):1445-52. PubMed ID: 24711551
[TBL] [Abstract][Full Text] [Related]
8. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
[TBL] [Abstract][Full Text] [Related]
9. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
[TBL] [Abstract][Full Text] [Related]
11. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
Cheung NK; Cheung IY; Kushner BH; Ostrovnaya I; Chamberlain E; Kramer K; Modak S
J Clin Oncol; 2012 Sep; 30(26):3264-70. PubMed ID: 22869886
[TBL] [Abstract][Full Text] [Related]
12. Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A.
Tse BC; Navid F; Billups CA; O'Donnell T; Hoehn ME
J AAPOS; 2015 Apr; 19(2):112-5. PubMed ID: 25818285
[TBL] [Abstract][Full Text] [Related]
13. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.
Metelitsa LS; Gillies SD; Super M; Shimada H; Reynolds CP; Seeger RC
Blood; 2002 Jun; 99(11):4166-73. PubMed ID: 12010822
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
Shusterman S; London WB; Gillies SD; Hank JA; Voss SD; Seeger RC; Reynolds CP; Kimball J; Albertini MR; Wagner B; Gan J; Eickhoff J; DeSantes KB; Cohn SL; Hecht T; Gadbaw B; Reisfeld RA; Maris JM; Sondel PM
J Clin Oncol; 2010 Nov; 28(33):4969-75. PubMed ID: 20921469
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
17. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.
Berthold F; Faldum A; Ernst A; Boos J; Dilloo D; Eggert A; Fischer M; Frühwald M; Henze G; Klingebiel T; Kratz C; Kremens B; Krug B; Leuschner I; Schmidt M; Schmidt R; Schumacher-Kuckelkorn R; von Schweinitz D; Schilling FH; Theissen J; Volland R; Hero B; Simon T
Ann Oncol; 2020 Mar; 31(3):422-429. PubMed ID: 32067684
[TBL] [Abstract][Full Text] [Related]
18. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021
[TBL] [Abstract][Full Text] [Related]
19. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
Fernandez MC; Krailo MD; Gerbing RR; Matthay KK
Cancer; 2000 Jun; 88(12):2838-44. PubMed ID: 10870069
[TBL] [Abstract][Full Text] [Related]
20. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.
Cheung NK; Cheung IY; Kramer K; Modak S; Kuk D; Pandit-Taskar N; Chamberlain E; Ostrovnaya I; Kushner BH
Int J Cancer; 2014 Nov; 135(9):2199-205. PubMed ID: 24644014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]